1. Home
  2. MX vs TLSA Comparison

MX vs TLSA Comparison

Compare MX & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magnachip Semiconductor Corporation

MX

Magnachip Semiconductor Corporation

HOLD

Current Price

$3.44

Market Cap

139.1M

Sector

Technology

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.08

Market Cap

155.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MX
TLSA
Founded
2003
2013
Country
South Korea
United Kingdom
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.1M
155.3M
IPO Year
2007
2017

Fundamental Metrics

Financial Performance
Metric
MX
TLSA
Price
$3.44
$1.08
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$5.75
N/A
AVG Volume (30 Days)
1.4M
199.2K
Earning Date
04-28-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
43.06
N/A
EPS
N/A
N/A
Revenue
$178,860,000.00
N/A
Revenue This Year
$8.55
N/A
Revenue Next Year
$6.37
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.18
$1.04
52 Week High
$9.86
$2.60

Technical Indicators

Market Signals
Indicator
MX
TLSA
Relative Strength Index (RSI) 34.07 39.65
Support Level $2.49 N/A
Resistance Level $4.76 $1.61
Average True Range (ATR) 0.30 0.11
MACD -0.07 -0.01
Stochastic Oscillator 7.82 2.44

Price Performance

Historical Comparison
MX
TLSA

About MX Magnachip Semiconductor Corporation

MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The Company operates within a single operating segment, Power Solutions business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: